Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Leflunomide 20 mg Tablets Under Fasting Conditions

This study has been completed.
Information provided by:
Teva Pharmaceuticals USA Identifier:
First received: January 30, 2009
Last updated: September 9, 2009
Last verified: September 2009
This study will compare the relative bioavailability (rate and extent of absorption) of 20 mg Leflunomide Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 20 mg ARAVA™ Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 20 mg tablet) in healthy adult subjects under fasting conditions.

Condition Intervention Phase
Drug: Leflunomide 20 mg Tablets
Drug: ARAVA™ 20 mg Tablets
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Relative Bioavailability Study of 20 mg Leflunomide Tablets Under Fasting Conditions

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceuticals USA:

Primary Outcome Measures:
  • Cmax - Maximum Observed Concentration - Metabolite A77 1726 in Plasma [ Time Frame: Blood samples collected over 72 hour period ]
  • AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours Post-dose - Metabolite A77 1726 [ Time Frame: Blood samples collected over 72 hour period ]

Enrollment: 84
Study Start Date: June 2002
Study Completion Date: July 2002
Primary Completion Date: July 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Leflunomide
Leflunomide 20 mg Tablet
Drug: Leflunomide 20 mg Tablets
1 x 20 mg, single-dose fasting
Active Comparator: Arava™
Arava™ 20 mg Tablet
Drug: ARAVA™ 20 mg Tablets
1 x 20 mg, single-dose fasting

Detailed Description:

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Screening Demographics: All subjects selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The weight range will not exceed ± 20% for height and body frame as per Desirable Weights for Adults - 1983 Metropolitan Height and Weight Table.
  • Screening procedures: Each subject will complete the screening process within 28 days prior to dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
  • Screening will include general observations, physical examination, demographics, medical and medication history, an electrocardiogram, sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.
  • The screening clinical laboratory procedures will include:

    1. Hematology: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet count;
    2. Clinical Chemistry: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total bilirubin, total protein, and alkaline phosphatase;
    3. HIV antibody and hepatitis B surface screens;
    4. Urinalysis: by dipstick; full microscopic examination if dipstick positive; and
    5. Urine Drug Screen: ethyl alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolites, opiates and phencyclidine.
    6. Serum Pregnancy Screen (female subjects only)
    7. Follicle Stimulating Hormone [FSH] (females only to verify postmenopausal status)
  • If male must be vasectomized (at least 3 months)
  • If female and:

    1. is postmenopausal for at least 1 year; or
    2. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion Criteria:

  • Subjects with a recent history of drug or alcohol addiction or abuse.
  • Subjects with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).
  • Subjects whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
  • Subjects demonstrating a positive hepatitis B surface antigen screen or reactive HIV antibody screen.
  • Subjects demonstrating a positive drug abuse screen when screened for this study.
  • Female subjects who are currently breastfeeding.
  • Female subjects demonstrating a positive pregnancy screen.
  • Subjects with a history of allergic response(s) to leflunomide or related drugs.
  • Subjects with a history of clinically significant allergies including drug allergies.
  • Subjects with a clinically significant illness during the 4 weeks prior to dosing (as determined by the clinical investigators).
  • Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing.
  • Subjects who report donating greater than 150 mL of blood within 30 days prior to dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
  • Subjects who have donated plasma (e.g. plasmapheresis) within 14 days prior to dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
  • Subjects who report receiving any investigational drug within 30 days prior to dosing.
  • Subjects who report taking any prescription medication in the 14 days prior to dosing, with the exception of postmenopausal women on HRT may continue their HRT and topical products without systemic absorption.
  • Subjects who report an intolerance of direct venipuncture.
  • Subjects who report consuming an abnormal diet during the 28 days prior to dosing.
  • Subjects who report taking any product containing leflunomide within 180 days of dosing.
  • Subjects who report taking any herbal products within 7 days prior to dosing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00834418

United States, North Dakota
PRACS Institute, Ltd.
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
Teva Pharmaceuticals USA
Principal Investigator: James D. Carlson, Pharm.D. PRACS Institute, Inc.
  More Information Identifier: NCT00834418     History of Changes
Other Study ID Numbers: R02-561
Study First Received: January 30, 2009
Results First Received: July 2, 2009
Last Updated: September 9, 2009

Keywords provided by Teva Pharmaceuticals USA:
Healthy Subjects

Additional relevant MeSH terms:
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on May 25, 2017